Company intelligence / Profile preview

Pygar family office

Ownership: Private
Development stage: Other

Overview

Pygar family office is described in a 2019 GenomSys Series A announcement as one of several European and U.S. family office investors, noted as being linked to the multinational diagnostic company Diasorin.[6] No evidence indicates that it is itself an operating biotech, pharma, or healthcare company, nor that it develops its own drug pipeline.

Industry: Investors

Partnerships

GenomSys (as an investor in its Series A financing round)[6]

Beyond the preview

Go deeper on Pygar family office.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pygar family office.

Explore the full profile